Navigation Links
Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
Date:1/18/2011

portant Safety Information:

OFIRMEV should be administered only as a 15 minute intravenous infusion. Do not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRMEV Prescribing Information, available at www.ofirmev.com or www.cadencepharm.com.

About Cadence Pharmaceuticals

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company committed to in-licensing, developing and commercializing proprietary product candidates to improve the lives of hospitalized patients. For more information about Cadence, please visit www.cadencepharm.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
3. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
4. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
6. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
7. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 Vestiage, Inc. ... company focused on science-based research and development, sales ... cosmeceuticals and nutraceuticals, announced today that it is ... for the sale of Reluma Skin Illuminating Facial ... and application by sending an email to info(at)vestiageinc(dot)com ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... present at the Jefferies 2013 Global Healthcare Conference to ... New York. Richard Smith ... Hai Tran , Chief Financial Officer, will present ... Daylight Time.   About BioScrip BioScrip, ...
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan ... human cord blood stem cell banking and therapeutics, announced ... the No. 16 Acorn Stairlifts Indy car driven by ... the remainder of the IZOD IndyCar 2013 season.   ... will work to support awareness of umbilical cord blood ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. ... for pain has reached an important milestone, as Virobay ... VBY-036 - a selective cathepsin S inhibitor.   ... a double-blind, randomized, placebo-controlled study designed to evaluate the ... VBY-036 in healthy adults. "The initiation of ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
... of enzymes routinely used to synthesizing some of nature's most ... new way to expand on nature's chemical creativity to make ... 1) in the journal Science , a team led ... the University of Wisconsin-Madison , describes the discovery of ...
... the new darling of Wall Street. In the past ... private equity firms, venture capital firms, and hedge funds. ... trading multiples in excess of $5 per gallon of ... EBITDA, and 1,000x trailing four quarters of net income. ...
... - When it comes to attracting venture capital, Wisconsin has ... Investors on the East and West coasts have basically stuck ... in the Heartland, with the exception of a few states ... have been signs that a few flights ferrying venture capitalists ...
Cached Biology Technology:UW finds new path to anti-cancer agents 2UW finds new path to anti-cancer agents 3Ethanol producers are at a crossroads 2Ethanol producers are at a crossroads 3Ethanol producers are at a crossroads 4Ethanol producers are at a crossroads 5Ethanol producers are at a crossroads 6That blip on the national venture capital radar screen may be Wisconsin 2That blip on the national venture capital radar screen may be Wisconsin 3
(Date:5/23/2013)... succeeded in treating cerebral palsy with autologous cord blood. ... 2.5 year old boy had been in a persistent ... two months after treatment with the cord blood containing ... months, the child learned to speak simple sentences and ... Korean study, dispel the long-held doubts about the effectiveness ...
(Date:5/23/2013)... world,s largest and fastest growing open-access publishers, announces ... in Bioengineering and Biotechnology . , A ... in Bioengineering and Biotechnology will provide a ... and biotechnology research to be disseminated and discussed. ... will provide an open-science and interactive web ...
(Date:5/23/2013)... In an age when microbial pathogens are growing increasingly ... infection, a team of Wisconsin scientists has synthesized a ... bacteria that cause staph infections. , Writing online in ... a group led by University of Wisconsin-Madison chemistry Professor ... "quorum sensing" behavior of Staphylococcus aureus , a ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2University of Wisconsin chemists find new compounds to curb staph infection 2
... invasive alien freshwater mussel species the zebra mussel and ... by calcium levels in streams and lakes and a new ... and American Southwest could be next in line for invasion. ... the online version of Frontiers in Ecology and the Environment, ...
... Dec. 3 A team of researchers from the Wellman ... Medical School (HMS) have developed an optical device that allows ... monitor the cells passing through its bloodstream. In ... by the Optical Society of America, the team describes how ...
... extraordinary ability to remember numerals that is superior to ... 4th issue of Current Biology, a publication of Cell ... biologists, who believe that humans are superior to chimpanzees ... University. No one can imagine that chimpanzeesyoung chimpanzees at ...
Cached Biology News:New map outlines risk of zebra mussel invasion 2New map outlines risk of zebra mussel invasion 3New map outlines risk of zebra mussel invasion 4Looking through the eyes of a mouse, scientists monitor circulating cells in its bloodstream 2Looking through the eyes of a mouse, scientists monitor circulating cells in its bloodstream 3Young chimps top adult humans in numerical memory 2
... 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: Heat inactivation ... Storage Conditions: 10mM Tris-HCl (pH 7.5), 100mM KCl, ... BSA, 50% glycerol. Shipping and Storage: Shipped on ... unit is defined as the amount of enzyme ...
... stainless-steel shaker flask clips, purpose-designed to firmly ... All clips are equipped with a top ... include a bottom retainer spring, and silicon ... expensive glassware. Clips include the required ...
ANTI DIPHTH TOX A SU...
... Assay Kit (E-22013) provides,researchers with a ... lysozyme,activity in solution. This fluorescence-based assay ... U/mL (Figure 1). The assay,measures lysozyme ... are labeled to such a degree ...
Biology Products: